These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27791595)

  • 1. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.
    Havas AP; Rodrigues KB; Bhakta A; Demirjian JA; Hahn S; Tran J; Scavello M; Tula-Sanchez AA; Zeng Y; Schmelz M; Smith CL
    Cancer Biol Ther; 2016 Dec; 17(12):1240-1252. PubMed ID: 27791595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis resistance, mitotic catastrophe, and loss of ploidy control in Burkitt lymphoma.
    Chumduri C; Gillissen B; Richter A; Richter A; Milojkovic A; Overkamp T; Müller A; Pott C; Daniel PT
    J Mol Med (Berl); 2015 May; 93(5):559-72. PubMed ID: 25548804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
    Marlow LA; Bok I; Smallridge RC; Copland JA
    Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
    Chien W; Lee DH; Zheng Y; Wuensche P; Alvarez R; Wen DL; Aribi AM; Thean SM; Doan NB; Said JW; Koeffler HP
    Mol Carcinog; 2014 Sep; 53(9):722-35. PubMed ID: 23475695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
    Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
    Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
    Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
    Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
    Monks A; Hose CD; Pezzoli P; Kondapaka S; Vansant G; Petersen KD; Sehested M; Monforte J; Shoemaker RH
    Anticancer Drugs; 2009 Sep; 20(8):682-92. PubMed ID: 19606018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
    Thompson RC; Vardinogiannis I; Gilmore TD
    PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe.
    Cornago M; Garcia-Alberich C; Blasco-Angulo N; Vall-Llaura N; Nager M; Herreros J; Comella JX; Sanchis D; Llovera M
    Cell Death Dis; 2014 Oct; 5(10):e1435. PubMed ID: 25275596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
    Chan D; Zheng Y; Tyner JW; Chng WJ; Chien WW; Gery S; Leong G; Braunstein GD; Koeffler HP
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1507-14. PubMed ID: 23824064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.
    Finnegan E; Ding W; Ude Z; Terer S; McGivern T; Blümel AM; Kirwan G; Shao X; Genua F; Yin X; Kel A; Fattah S; Myer PA; Cryan SA; Prehn JHM; O'Connor DP; Brennan L; Yochum G; Marmion CJ; Das S
    Cell Oncol (Dordr); 2024 Apr; 47(2):533-553. PubMed ID: 37934338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
    Chang WL; Yu CC; Chen CS; Guh JH
    Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    To KK; Tong WS; Fu LW
    Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
    El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
    Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
    Qian X; Ara G; Mills E; LaRochelle WJ; Lichenstein HS; Jeffers M
    Int J Cancer; 2008 Mar; 122(6):1400-10. PubMed ID: 18027850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.